APEXNK
Live / Applied — Third extension granted (statement of use) (as of 24 Nov 2025)
What this means for you
Not registered yet, but its 09 Mar 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97830057
- Mark type
- Stylized text
- Filed
- 09 Mar 2023
- Published for opposition
- 02 Apr 2024
- Attorney of record
- Joseph A. Bruce
Goods and services
- Class 005 — Pharmaceuticals: Immunostimulants; Pre-filled cell-based medicinal products, namely, medicinal products for aging, oncology and autoimmune disease; Biological tissue cultures for medical purposes; Anti-cancer preparations; Medicines for the treatment of cancer; Active pharmaceutical ingredient for western medicine, namely, pharmaceutical agents for aging, oncology and autoimmune disease; Anti-cancer agents; Antivirals; Biological preparations for the treatment of cancer; Biocides; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer treatment; Blood for medical purposes; Adjuvants for medical purposes; Albuminous preparations for medical purposes; Pharmaceuticals, namely, immunotherapy being immunostimulators; Pharmaceutical preparations for the treatment of cancer; Stem cells for medical purposes; Reagents for medical use; Diagnostic reagents for medical use
- Class 042 — Scientific and technological services: Biological research; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Medical and scientific research, namely, conducting clinical trials for others; Research and development in the pharmaceutical and biotechnology fields; Medical research services; Medical research and development in the field of cancer immunotherapy; Research and development of new products for others; Technological research in the field of cancer immunotherapy; Conducting technical project studies in the nature of scientific feasibility studies; Technical writing for others; Scientific laboratory services; Scientific research; Technological consultancy services in the field of cancer immunotherapy; Scientific and technological research relating to cancer immunotherapy; Culturing of cells for others for scientific research purposes; New product design services; Packaging design; Graphic design services; Custom design of prototypes; Graphic design of logos; Quality control of goods and services; Product quality testing services
Owner
- Apexcella Biomedical Inc., Taipei City, TW
- Apexcella Biomedical Inc., Taipei City, TW
Prosecution history
- 24 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Nov 2025 — SOU EXTENSION 3 GRANTED
- 23 Nov 2025 — SOU EXTENSION 3 FILED
- 23 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 15 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 May 2025 — SOU EXTENSION 2 GRANTED
- 15 May 2025 — SOU EXTENSION 2 FILED
- 14 May 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 Nov 2024 — SOU EXTENSION 1 GRANTED
- 21 Nov 2024 — SOU EXTENSION 1 FILED
- 21 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 21 Aug 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 21 Aug 2024 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 21 Aug 2024 — TEAS CHANGE OF OWNER ADDRESS RECEIVED